Information Provided By:
Fly News Breaks for January 10, 2018
GHDX
Jan 10, 2018 | 09:51 EDT
Cowen analyst Doug Schenkel noted that the U.K.'s National Institute for Health and Care Excellence, or NICE, reversed a previous decision with new draft guidance that does not recommend Genomic Health's Oncotype test in guiding chemotherapy decisions for breast cancer patients. He finds this "somewhat surprising" given the test's inclusion in other international guidelines and think this could lead to some slight tempering of expectations if finalized. Schenkel has a Market Perform rating on Genomic Health shares.
News For GHDX From the Last 2 Days
There are no results for your query GHDX